Works by Burke, John M.

Results: 132
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13

    ACCP Clinical Pharmacist Competencies.

    Published in:
    Pharmacotherapy, 2017, v. 37, n. 5, p. 630, doi. 10.1002/phar.1923
    By:
    • Saseen, Joseph J.;
    • Ripley, Toni L.;
    • Bondi, Deborah;
    • Burke, John M.;
    • Cohen, Lawrence J.;
    • McBane, Sarah;
    • McConnell, Karen J.;
    • Sackey, Bryan;
    • Sanoski, Cynthia;
    • Simonyan, Anahit;
    • Taylor, Jodi;
    • Vande Griend, Joseph P.
    Publication type:
    Article
    14
    15
    16
    17
    18
    19

    A systems pharmacology model for gene therapy in sickle cell disease.

    Published in:
    CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 7, p. 696, doi. 10.1002/psp4.12638
    By:
    • Zheng, Bo;
    • Wille, Lucia;
    • Peppel, Karsten;
    • Hagen, David;
    • Matteson, Andrew;
    • Ahlers, Jeffrey;
    • Schaff, James;
    • Hua, Fei;
    • Yuraszeck, Theresa;
    • Cobbina, Enoch;
    • Apgar, Joshua F.;
    • Burke, John M.;
    • Roberts, John;
    • Das, Raibatak
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    Improvements in Health-related Quality of Life and Symptoms in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Final Results From the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 2, p. 121, doi. 10.1016/j.clml.2021.09.008
    By:
    • Danilov, Alexey V.;
    • Yimer, Habte A.;
    • Boxer, Michael A.;
    • Burke, John M.;
    • Babu, Sunil;
    • Jia Li;
    • Yong Mun;
    • Trask, Peter C.;
    • Masaquel, Anthony S.;
    • Sharman, Jeff P.
    Publication type:
    Article
    33

    IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S404, doi. 10.1016/S2152-2650(21)01912-1
    By:
    • Ghosh, Nilanjan;
    • Zinzani, Pier Luigi;
    • Samaniego, Felipe;
    • Jurczak, Wojciech;
    • Derenzini, Enrico;
    • Reeves, James A.;
    • Knopinska-Posluszny, Wanda;
    • Cheah, Chan Y.;
    • Phillips, Tycel;
    • Lech-Maranda, Ewa;
    • Cheson, Bruce;
    • Calmi, Paolo;
    • Grosicki, Sebastian;
    • Leslie, Lori A.;
    • Chavez, Julio C.;
    • Fonseca, Gustavo;
    • Babu, Sunil;
    • Hodson, Daniel J.;
    • Shao, Spencer H.;
    • Burke, John M.
    Publication type:
    Article
    34

    ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S376, doi. 10.1016/S2152-2650(21)01860-7
    By:
    • Vitolo, Umberto;
    • Nowakowski, Grzegorz S.;
    • Burke, John M.;
    • Fox, Christopher P.;
    • Trneny, Marek;
    • Chiappella, Annalisa;
    • Tillmanns, Sascha;
    • Sporchia, Andrea;
    • Brugger, Wolfram;
    • Lenz, Georg
    Publication type:
    Article
    35

    Poster: IBCL-203: Umbralisib, a PI3Kδ/CK1ε Dual Inhibitor Demonstrates Marked Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (iNHL): Results from the Phase 2 Global UNITY-NHL Trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01537-8
    By:
    • Ghosh, Nilanjan;
    • Zinzani, Pier Luigi;
    • Samaniego, Felipe;
    • Jurczak, Wojciech;
    • Derenzini, Enrico;
    • Reeves, James A.;
    • Knopinska-Posluszny, Wanda;
    • Cheah, Chan Y.;
    • Phillips, Tycel;
    • Lech-Maranda, Ewa;
    • Cheson, Bruce;
    • Caimi, Paolo;
    • Grosicki, Sebastian;
    • Leslie, Lori A.;
    • Chavez, Julio C.;
    • Fonseca, Gustavo;
    • Babu, Sunil;
    • Hodson, Daniel J.;
    • Shao, Spencer H.;
    • Burke, John M.
    Publication type:
    Article
    36

    Poster: ABCL-021: FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-CHOP vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01533-0
    By:
    • Vitolo, Umberto;
    • Nowakowski, Grzegorz S.;
    • Burke, John M.;
    • Fox, Christopher P.;
    • Trneny, Marek;
    • Chiappella, Annalisa;
    • Tillmanns, Sascha;
    • Sporchia, Andrea;
    • Brugger, Wolfram;
    • Lenz, Georg
    Publication type:
    Article
    37
    38
    39
    40
    41
    42
    43
    44

    A Self-Assessment Guide for Resident Teaching Experiences.

    Published in:
    Pharmacotherapy, 2016, v. 36, n. 6, p. e58, doi. 10.1002/phar.1768
    By:
    • Engle, Janet P.;
    • Franks, Amy M.;
    • Ashjian, Emily;
    • Bingham, Angela L.;
    • Burke, John M.;
    • Erstad, Brian L.;
    • Haines, Seena L.;
    • Hilaire, Michelle L.;
    • Rager, Michelle L.;
    • Wienbar, Rebecca
    Publication type:
    Article
    45
    46
    47
    48
    49
    50